Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Published 2018 View Full Article

Authors

Keywords

Next generation sequencing (NGS), Precision medicine, Genomic aberrations, Regulatory issues, Ethics, Patient advocacy, Bioinformatics, Cancer screening and prevention

Journal

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Volume 37, Issue 1, Pages -

Publisher

Springer Nature

Online

2018-03-05

DOI

10.1186/s13046-018-0702-x

References

View 3 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now